Viking Therapeutics, Inc.
VKTX
$24.99
-$0.67-2.61%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Net Income | -45.63M | -35.42M | -24.94M | -22.25M | -27.36M |
| Total Depreciation and Amortization | 111.00K | 110.00K | 87.00K | 75.00K | 74.00K |
| Total Amortization of Deferred Charges | 24.00K | 24.00K | 24.00K | 18.00K | 28.00K |
| Total Other Non-Cash Items | 8.23M | 1.65M | 3.90M | 1.66M | 5.17M |
| Change in Net Operating Assets | -15.06M | 2.46M | -1.03M | -8.01M | 15.95M |
| Cash from Operations | -52.33M | -31.18M | -21.96M | -28.51M | -6.13M |
| Capital Expenditure | -- | -- | -- | -- | -- |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | 63.25M | 6.58M | 25.90M | -126.06M | -459.79M |
| Cash from Investing | 63.25M | 6.58M | 25.90M | -126.06M | -459.79M |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | 349.00K | 1.00M | 2.52M | 2.91M | 648.14M |
| Repurchase of Common Stock | -- | 0.00 | 0.00 | 0.00 | -42.10M |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | 349.00K | 1.00M | 2.52M | 2.91M | 606.04M |
| Foreign Exchange rate Adjustments | 1.00K | -74.00K | -29.00K | 3.00K | -48.00K |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | 11.26M | -23.67M | 6.43M | -151.66M | 140.06M |